These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22471166)

  • 1. Rules for evaluating biosimilars put applicants through hoops.
    Morrow T
    Manag Care; 2012 Mar; 21(3):56-7. PubMed ID: 22471166
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA and congress: differing agendas?
    Lipman AG
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):116-7. PubMed ID: 20504131
    [No Abstract]   [Full Text] [Related]  

  • 3. A sick agency in need of a cure? Recall of a popular pain drug has focused attention on government drug regulation.
    Spake A
    US News World Rep; 2004 Dec; 137(21):32-3, 36. PubMed ID: 15636503
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulation of follow-on biologics.
    Frank RG
    N Engl J Med; 2007 Aug; 357(9):841-3. PubMed ID: 17761588
    [No Abstract]   [Full Text] [Related]  

  • 5. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It?
    Hyman DA; Silver C
    J Leg Med; 2019; 39(2):137-149. PubMed ID: 31503533
    [No Abstract]   [Full Text] [Related]  

  • 6. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
    Silbermann JM
    J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
    [No Abstract]   [Full Text] [Related]  

  • 7. A bitter pill for one Merck critic.
    McLean B
    Fortune; 2004 Dec; 150(12):58. PubMed ID: 15617422
    [No Abstract]   [Full Text] [Related]  

  • 8. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 9. Criminal conviction for distribution of a drug not approved by the FDA.
    Brushwood DB
    Am J Hosp Pharm; 1991 Apr; 48(4):747-9. PubMed ID: 2042679
    [No Abstract]   [Full Text] [Related]  

  • 10. Adequate controls for new drugs: good manufacturing practice and the 1938 federal Food, Drug, and Cosmetic Act.
    Cooper DE
    Pharm Hist; 2002; 44(1):12-23. PubMed ID: 12068915
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical product integrity: can the FDA assure quality?
    Bernstein I
    Manag Care; 2004 Mar; 13(3 Suppl):30-3. PubMed ID: 15074168
    [No Abstract]   [Full Text] [Related]  

  • 12. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
    Hubbard WK
    Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
    [No Abstract]   [Full Text] [Related]  

  • 13. The state of the art in the development of biosimilars.
    McCamish M; Woollett G
    Clin Pharmacol Ther; 2012 Mar; 91(3):405-17. PubMed ID: 22318617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA, industry collaborate to strengthen painkiller restrictions.
    Sipkoff M
    Manag Care; 2009 Apr; 18(4):10-1. PubMed ID: 19472560
    [No Abstract]   [Full Text] [Related]  

  • 15. The Food and Drug Administration and its problems.
    Iglehart JK
    N Engl J Med; 1991 Jul; 325(3):217-20. PubMed ID: 2052069
    [No Abstract]   [Full Text] [Related]  

  • 16. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract]   [Full Text] [Related]  

  • 17. Trying times at the FDA--the challenge of ensuring the safety of imported pharmaceuticals.
    Schweitzer SO
    N Engl J Med; 2008 Apr; 358(17):1773-7. PubMed ID: 18434648
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulatory science and the role of the regulator in biomedical innovation.
    Honig PK; Huang SM
    Clin Pharmacol Ther; 2012 Mar; 91(3):347-52. PubMed ID: 22343804
    [No Abstract]   [Full Text] [Related]  

  • 19. Maker of growth hormone feels long arm of law.
    Nordenberg T
    FDA Consum; 1999; 33(5):33. PubMed ID: 10522170
    [No Abstract]   [Full Text] [Related]  

  • 20. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
    Willis KD
    Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.